TRB 071
Alternative Names: TRB-071Latest Information Update: 18 Aug 2025
At a glance
- Originator TRexBio
- Class
- Mechanism of Action Regulatory T-lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Immunological disorders
Most Recent Events
- 18 Aug 2025 Preclinical trials in Immunological disorders in USA (unspecified route) prior to August 2025 (TRex Bio pipeline, August 2025)
- 30 Dec 2022 Early research in Unspecified in USA (unspecified route) (TRexBio pipeline, December 2022)